Filing Flows › BioNexus Gene Lab (BGLC) › R&D spending
BioNexus Gene Lab (BGLC) R&D spending by quarter
BioNexus Gene Lab's R&D spending was $14K in Q1 2026 (first quarter 2026), +31% from Q4 2025. Over the last 5 quarters it ranged from $11K (Q4 2025) to $17K (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $14K | +31% | +19% |
| Q4 2025 | $11K | -25% | -36% |
| Q3 2025 | $15K | +23% | — |
| Q1 2025 | $12K | -30% | — |
| Q4 2024 | $17K | — | — |
Q1 2026 at a glance
BioNexus Gene Lab, Q1 2026: revenue $23K (-99% year over year), net loss $544K, operating cash flow −$148K. The chart follows the revenue to costs, profit and cash.
Questions
What is BioNexus Gene Lab's R&D spending?
BioNexus Gene Lab's R&D spending was $14K in Q1 2026 (first quarter 2026), +31% from Q4 2025.
How has BioNexus Gene Lab's R&D spending changed?
Over the last 5 quarters it ranged from $11K (Q4 2025) to $17K (Q4 2024).